Literature DB >> 19780894

Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.

D Allan Butterfield1, Miranda L Bader Lange.   

Abstract

Enolase enzymes are abundantly expressed, cytosolic carbon-oxygen lyases known for their role in glucose metabolism. Recently, enolase has been shown to possess a variety of different regulatory functions, beyond glycolysis and gluconeogenesis, associated with hypoxia, ischemia, and Alzheimer's disease (AD). AD is an age-associated neurodegenerative disorder characterized pathologically by elevated oxidative stress and subsequent damage to proteins, lipids, and nucleic acids, appearance of neurofibrillary tangles and senile plaques, and loss of synapse and neuronal cells. It is unclear if development of a hypometabolic environment is a consequence of or contributes to AD pathology, as there is not only a significant decline in brain glucose levels in AD, but also there is an increase in proteomics identified oxidatively modified glycolytic enzymes that are rendered inactive, including enolase. Previously, our laboratory identified alpha-enolase as one the most frequently up-regulated and oxidatively modified proteins in amnestic mild cognitive impairment (MCI), early-onset AD, and AD. However, the glycolytic conversion of 2-phosphoglycerate to phosphoenolpyruvate catalyzed by enolase does not directly produce ATP or NADH; therefore it is surprising that, among all glycolytic enzymes, alpha-enolase was one of only two glycolytic enzymes consistently up-regulated from MCI to AD. These findings suggest enolase is involved with more than glucose metabolism in AD brain, but may possess other functions, normally necessary to preserve brain function. This review examines potential altered function(s) of brain enolase in MCI, early-onset AD, and AD, alterations that may contribute to the biochemical, pathological, clinical characteristics, and progression of this dementing disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19780894      PMCID: PMC4454338          DOI: 10.1111/j.1471-4159.2009.06397.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  226 in total

1.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

Authors:  Barbara L Apostol; Katalin Illes; Judit Pallos; Laszlo Bodai; Jun Wu; Andrew Strand; Erik S Schweitzer; James M Olson; Aleksey Kazantsev; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2005-12-05       Impact factor: 6.150

Review 2.  The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives.

Authors:  M R Palmert; M B Podlisny; T E Golde; M L Cohen; D M Kovacs; R E Tanzi; J F Gusella; P J Whitehouse; D S Witker; T Oltersdorf
Journal:  Prog Clin Biol Res       Date:  1989

Review 3.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

Review 4.  Metabolic regulation of gene transcription in mammals.

Authors:  H C Towle
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

5.  Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain.

Authors:  D A Willoughby; I Rozovsky; A C Lo; C E Finch
Journal:  J Mol Neurosci       Date:  1995       Impact factor: 3.444

6.  Is tissue-type plasminogen activator a neuromodulator?

Authors:  Mónica Fernández-Monreal; José P López-Atalaya; Karim Benchenane; Frederic Léveillé; Mathias Cacquevel; Laurent Plawinski; Eric T MacKenzie; Guojun Bu; Alain Buisson; Denis Vivien
Journal:  Mol Cell Neurosci       Date:  2004-04       Impact factor: 4.314

7.  Characterization of the interaction of yeast enolase with polynucleotides.

Authors:  A G al-Giery; J M Brewer
Journal:  Biochim Biophys Acta       Date:  1992-09-23

8.  Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites.

Authors:  J Q Trojanowski; M Mawal-Dewan; M L Schmidt; J Martin; V M Lee
Journal:  Brain Res       Date:  1993-08-06       Impact factor: 3.252

9.  Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease.

Authors:  Tanea Reed; Marzia Perluigi; Rukhsana Sultana; William M Pierce; Jon B Klein; Delano M Turner; Raffaella Coccia; William R Markesbery; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2008-01-05       Impact factor: 5.996

10.  Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease.

Authors:  B T Hyman; R E Tanzi; K Marzloff; R Barbour; D Schenk
Journal:  J Neuropathol Exp Neurol       Date:  1992-01       Impact factor: 3.685

View more
  63 in total

1.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

2.  An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors:  Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-08-20       Impact factor: 7.376

Review 3.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

4.  Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model.

Authors:  Cheng Zhang; Ching-Chang Kuo; Setareh H Moghadam; Louise Monte; Kenner C Rice; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  Elevation of glutathione as a therapeutic strategy in Alzheimer disease.

Authors:  Chava B Pocernich; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2011-10-12

6.  Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-β peptide of amyloid precursor protein.

Authors:  R A S Robinson; M B Lange; R Sultana; V Galvan; J Fombonne; O Gorostiza; J Zhang; G Warrier; J Cai; W M Pierce; D E Bredesen; D A Butterfield
Journal:  Neuroscience       Date:  2011-01-09       Impact factor: 3.590

7.  Amyloid beta-heme peroxidase promoted protein nitrotyrosination: relevance to widespread protein nitration in Alzheimer's disease.

Authors:  Can Yuan; Lian Yi; Zhen Yang; Qingqing Deng; Yi Huang; Hailing Li; Zhonghong Gao
Journal:  J Biol Inorg Chem       Date:  2011-09-14       Impact factor: 3.358

8.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

Review 9.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.